JP2020523334A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523334A5
JP2020523334A5 JP2019568107A JP2019568107A JP2020523334A5 JP 2020523334 A5 JP2020523334 A5 JP 2020523334A5 JP 2019568107 A JP2019568107 A JP 2019568107A JP 2019568107 A JP2019568107 A JP 2019568107A JP 2020523334 A5 JP2020523334 A5 JP 2020523334A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
vibeglon
dosage
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568107A
Other languages
English (en)
Japanese (ja)
Other versions
JP7670461B2 (ja
JP2020523334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/054070 external-priority patent/WO2018224990A1/en
Publication of JP2020523334A publication Critical patent/JP2020523334A/ja
Publication of JP2020523334A5 publication Critical patent/JP2020523334A5/ja
Priority to JP2023019236A priority Critical patent/JP2023058635A/ja
Application granted granted Critical
Publication of JP7670461B2 publication Critical patent/JP7670461B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568107A 2017-06-06 2018-06-06 過活動膀胱の治療のためのビベグロンの投薬 Active JP7670461B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023019236A JP2023058635A (ja) 2017-06-06 2023-02-10 過活動膀胱の治療のためのビベグロンの投薬

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762516013P 2017-06-06 2017-06-06
US62/516,013 2017-06-06
US201862635310P 2018-02-26 2018-02-26
US62/635,310 2018-02-26
US201862637949P 2018-03-02 2018-03-02
US62/637,949 2018-03-02
PCT/IB2018/054070 WO2018224990A1 (en) 2017-06-06 2018-06-06 Dosing of vibegron for treatment of overactive bladder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023019236A Division JP2023058635A (ja) 2017-06-06 2023-02-10 過活動膀胱の治療のためのビベグロンの投薬

Publications (3)

Publication Number Publication Date
JP2020523334A JP2020523334A (ja) 2020-08-06
JP2020523334A5 true JP2020523334A5 (enExample) 2021-07-26
JP7670461B2 JP7670461B2 (ja) 2025-04-30

Family

ID=62815098

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019568107A Active JP7670461B2 (ja) 2017-06-06 2018-06-06 過活動膀胱の治療のためのビベグロンの投薬
JP2023019236A Withdrawn JP2023058635A (ja) 2017-06-06 2023-02-10 過活動膀胱の治療のためのビベグロンの投薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023019236A Withdrawn JP2023058635A (ja) 2017-06-06 2023-02-10 過活動膀胱の治療のためのビベグロンの投薬

Country Status (9)

Country Link
US (2) US20210077496A1 (enExample)
EP (1) EP3634488A1 (enExample)
JP (2) JP7670461B2 (enExample)
KR (2) KR20200012939A (enExample)
CN (1) CN110869053A (enExample)
AU (2) AU2018282105A1 (enExample)
CA (1) CA3064973A1 (enExample)
MX (1) MX2023000187A (enExample)
WO (1) WO2018224990A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018282104B2 (en) 2017-06-06 2024-07-11 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
CA3085745A1 (en) * 2017-12-21 2019-06-27 Kyorin Pharmaceutical Co., Ltd. An agent for treating nocturnal pollakiuria
EP3890743A1 (en) * 2018-12-05 2021-10-13 Urovant Sciences GmbH Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) * 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
TW202239412A (zh) * 2020-12-22 2022-10-16 瑞士商優洛凡特科學公司 使用維貝格隆（ｖｉｂｅｇｒｏｎ）並監測地高辛（ｄｉｇｏｘｉｎ）以治療膀胱過動症的方法
KR20250051257A (ko) 2023-10-10 2025-04-17 (주)케이아트휀스 지주파이프 롤포밍 장치

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
BR112012007829A2 (pt) * 2009-10-07 2015-09-22 Merck Sharp & Dohme método para tratar bexiga hiperativa, e, composição farmacêutica.
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
LT2968269T (lt) 2013-03-15 2019-10-25 Merck Sharp & Dohme Beta 3 agonistų ir tarpinių junginių gamybos būdas
EP3463312A4 (en) * 2016-06-03 2020-02-05 Velicept Therapeutics, Inc. DOSAGE DIAGRAMS FOR BETA-3 ADRENERGIC RECEPTOR AGONISTS AND ANTI-MUSCARIN AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY SYMPTOMS AND VESICAL HYPERACTIVITY

Similar Documents

Publication Publication Date Title
JP2020523334A5 (enExample)
US8071557B2 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
CN105120872B (zh) 包含15-hepe的组合物以及其使用方法
JP2020522560A5 (enExample)
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2019218379A5 (enExample)
SK284937B6 (sk) Použitie prokineticky účinného antiemetika a tramadolu na výrobu liečiva na liečenie migrény
JP2016507500A5 (enExample)
JP2016505050A5 (enExample)
CN113768863A (zh) L-鸟氨酸苯乙酸盐制剂
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
CN113876775B (zh) 一种青藤碱或其药物可接受的盐作为治疗动脉性肺动脉高压药物的用途
CN100418526C (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
JP2022133449A (ja) レボドパ分割用量組成物および使用
JP2019535830A5 (enExample)
CN102379877A (zh) 一种预防或治疗心肌缺血型慢性心力衰竭西药复方及用途
JP5296968B2 (ja) イブプロフェン含有経口用医薬組成物
JPWO2023049920A5 (enExample)
JP2021169472A5 (enExample)
US20190381034A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
KR100379155B1 (ko) 새로운 진통제 조성물
Green et al. Nicotine: therapeutic potential for the treatment of ulcerative colitis
NZ759999B2 (en) Use of vibegron to treat overactive bladder
NZ759999A (en) Use of vibegron to treat overactive bladder
JP2007513095A5 (enExample)